OptiNose Inc
OPTN
Company Profile
Business description
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
Contact
1020 Stony Hill Road
Suite 300
YardleyPA19067
USAT: +1 267 364-3500
E: investors@optinose.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
132
Stocks News & Analysis
stocks
2 ASX shares among our best ideas report earnings
These two shares are included on our March Global Equity Best Ideas list.
stocks
Potential moonshot investment at ASX tech leader
Investors may be over optimistic about the prospects for a new revenue source.
stocks
These ASX earnings season dogs may have fallen too far
The longer term outlook for these moated companies looks far brighter than markets seem to be giving them credit for.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,420.90 | 57.90 | -0.68% |
| CAC 40 | 8,125.66 | 74.05 | -0.90% |
| DAX 40 | 22,827.12 | 319.90 | -1.38% |
| Dow JONES (US) | 43,191.24 | 649.67 | -1.48% |
| FTSE 100 | 8,819.95 | 51.36 | -0.58% |
| HKSE | 22,941.77 | 64.50 | -0.28% |
| NASDAQ | 18,350.19 | 497.09 | -2.64% |
| Nikkei 225 | 37,331.18 | 454.29 | -1.20% |
| NZX 50 Index | 12,469.71 | 80.34 | -0.64% |
| S&P 500 | 5,849.72 | 104.78 | -1.76% |
| S&P/ASX 200 | 8,198.10 | 47.60 | -0.58% |
| SSE Composite Index | 3,324.21 | 7.28 | 0.22% |